Navigation Links
Pro-Dex, Inc. Announces Fiscal Second Quarter And Six-Month Results
Date:1/10/2013

IRVINE, Calif., Jan. 10, 2013 /PRNewswire/ -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal second quarter and six months ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c)

Quarter Ended December 31, 2012Sales for the quarter ended December 31, 2012 decreased 25% to $3.0 million from $4.0 million for the corresponding quarter in 2011.  As the Company has previously discussed, this decrease was primarily the result of reductions in purchases of the Company's powered surgical instrument products by its former largest customer, partially offset by increases in such surgical instrument sales to other customers.  Excluding sales to the Company's former largest customer, which represented a reduction of $1.5 million in the quarter ended December 31, 2012 from the corresponding quarter in 2011, sales increased $524,000, or 25%, in the quarter ended December 31, 2012.

Gross profit for the quarter ended December 31, 2012 was $1.0 million, or 34%, compared to gross profit of $1.2 million, or 31%, for the year-ago period.  The increase in gross profit as a percentage of sales from 2011 to 2012 was due primarily to a reduction in warranty costs and improvements in manufacturing efficiencies, partially offset by unfavorable changes in product mix. 

Operating expenses, which include selling, general and administrative, and research and development expenses, for the quarter ended December 31, 2012 decreased 10% to $1.4 million from $1.6 million in the prior year's corresponding quarter.  This decrease was attributable to the effects of reduced employee compensation, other operating expense cuts, and the utilization of engineering resources in contractual revenue-producing activities. Included in operating expenses for the quarter ended December 31, 2012 was $42,000 of legal and other costs associated with the contested election of directors, without which such costs the reduction in operating expenses would have been 12%.

Loss from continuing operations for the quarter ended December 31, 2012 was $364,000, compared to a loss from continuing operations of $329,000 in the corresponding quarter in 2011.  Net loss for the quarter ended December 31, 2012 was $348,000, or $0.11 per diluted share, compared to a net loss of $292,000, or $0.09 per diluted share, for the corresponding quarter in 2011.  Earnings before interest, income taxes and depreciation ("EBITDA") for the quarter ended December 31, 2012 was a loss of $196,000, compared to a loss of $130,000 in the corresponding quarter in 2011.

During the quarter ended December 31, 2012, the Company used $619,000 of cash in operating activities.  This use of cash reflects primarily payments made in the second fiscal quarter for the build-up of inventory in first fiscal quarter in anticipation of customer orders and pursuant to the Company's operating plan, one of the foundational objectives of which is to reduce production lead times.

Six Months Ended December 31, 2012Sales for the six months ended December 31, 2012 decreased 29% to $6.5 million from $9.1 million in the corresponding six-month period in 2011.  Excluding sales to the Company's former largest customer, which represented a reduction of $3.8 million in the six months ended December 31, 2012 from the corresponding period in 2011, sales for the six months ended December 31, 2012 increased $1.2 million, or 25%, in the six months ended December 31, 2012. During the six months ended December 31, 2012, the Company received new orders of $9.4 million, compared to $2.8 million in the corresponding period in 2011, excluding orders received from the former largest customer.  The book to bill ratio for the six months ended December 31, 2012 was 1.5.

For the six months ended December 31, 2012, gross profit was $2.3 million, or 35%, compared to $3.4 million and 37%, respectively, for the corresponding period in 2011. The decrease in gross profit as a percentage of sales from 2011 to 2012 resulted primarily from reduced manufacturing efficiencies and unfavorable changes in product mix, partially offset by a reduction in warranty costs.

Operating expenses for the six months ended December 31, 2012 decreased 19% to $2.7 million, from $3.3 million in the corresponding six-month period of 2011. This decrease was attributable to the effects of reduced employee compensation, other operating expense cuts, and the utilization of engineering resources in contractual revenue-producing activities.

For the six months ended December 31, 2012, loss from continuing operations was $418,000, compared to income from continuing operations of $17,000 for the corresponding period in 2011.  Net loss for the 2012 six-month period was $365,000, or $0.11 per diluted share, as compared to net income of $154,000, or $0.05 per diluted share, for the corresponding period in 2011.  EBITDA for the six months ended December 31, 2012 was a loss of $55,000, compared to income of $473,000 in the corresponding period one year ago.

During the six months ended December 31, 2012, the Company used $791,000 of cash in operating activities.  This use of cash reflects primarily the previously mentioned build-up of inventory in first fiscal quarter.  In addition, as announced previously, in September 2012 the Company repaid the entire outstanding balance on the term loan from Union Bank amounting to $685,000.  As a result of the foregoing, cash on hand at December 31, 2012 was $2.5 million, compared to $4.1 million at June 30, 2012.

Michael J. Berthelot, the Company's President and Chief Executive Officer, commented, "We believe that the results of the quarter and six months ended December 31, 2012 reflect continued progress on our strategy to move our company forward.  We believe that our continuing efforts to attract, quote on and win new business are showing results.  In the six months ended December 31, 2011, the first half of fiscal year 2012, we submitted five proposals to potential customers, and submitted eight proposals for the entire fiscal year.  So far in this current fiscal year we have already submitted eight proposals in the six months ended December 31, 2012 and have won one of them.  As important, the value of the current year proposals in both non-recurring engineering and production value materially exceed those from last year.  While we can offer no assurances that we will win any of the business upon which we have quoted, we know that we cannot win any business on which we do not quote.  We continue to win business from new customers as well as current customers, as shown in a 25% increase in sales of powered surgical instruments to customers other than our former largest customer compared to last year's corresponding quarter and six-months, and continue to build our backlog with a book to bill ratio of 1.5 for both the quarter and the six months ended December 31, 2012." 

"Our continuing efforts at cost reduction and improved manufacturing efficiencies led to our gross margin for the quarter ended December 31, 2012 increasing to 34% from 31% in last year's corresponding quarter in spite of a 25% reduction in sales volume and an unfavorable shift in product mix," said Mr. Berthelot.  "Our programs to reduce cost in every non-manufacturing department continue to bear fruit, as evidenced by the 10% reduction in operating costs for the quarter from last year.  It is important to point out that $42,000 of the general and administrative costs for the quarter are associated with the contested election of directors that we would not normally incur." 

Mr. Berthelot said, "With respect to product innovation and quality improvement, much of the new proposals discussed above revolve around our Pro-Driver platform and involve various derivatives and modifications to our basic product. While the time-consuming process from initial meeting to proposal, development, testing, acceptance and production may run from twelve to eighteen months and involve resources from sales and marketing, engineering, quality assurance, operations and finance, we have achieved success in winning customer acceptance of our development process and we hope that success will continue on if and when the product is released to production.  We have been working on an expansion of our dental product line for several months.  With a resurgent marketing effort, we hope to launch a new product that will fill out our dental product line during the next six months. As we push forward our product innovation and development efforts and move to protect our intellectual property, we are seeing greater spending on legal fees associated with patent and trademark filings, which aggregated $22,000 and $47,000 during the quarter and six months ended December 31, 2012, respectively."

Mr. Berthelot continued, "Lead times for our most significant products continue to improve.  As a result of a change in our production and planning processes, we are now able to ship our standard Pro-Drivers, the product which is currently attracting the most interest from potential customers, within two days of order for small volumes and two weeks for larger volumes, compared to quoted lead times of sixteen weeks in last fiscal year's fourth quarter.  We believe that an improved responsiveness to customer requests for samples and small volume test and evaluation lots will help us in our efforts to participate from the early phases of new customer programs."

"While we are making progress, we still have much to do.  The second quarter was, we believe, the toughest of the fiscal year, partly due to our shutdown of operations for two weeks during the quarter for the Thanksgiving, Christmas and New Year holidays as part of our cost reduction program.  Our backlog is strong for the second half of fiscal 2013.  We expect to continue to press down on our cost structure while increasing engineering resources.  We expect the programs and projects that we have begun to move our company forward and to build value for every shareholder."

"Of course," Mr. Berthelot noted, "we appreciate the support of each and every shareholder as we pursue our strategy amidst the distraction and diversion of resources due to the contested election of directors.  We understand that there have been some logistical problems in our proxy materials arriving to our shareholders on the West Coast.  If you have not yet received the Company's proxy materials which include the BLUE proxy card, we encourage you to contact our proxy solicitor, AST Phoenix Advisers, at 1-866-721-1318 and ask for the materials to be sent to you.  We ask that all of our shareholders vote for the Pro-Dex director nominees using the BLUE proxy card as quickly as possible, and we thank you for your support."

Teleconference Information:Investors and analysts are invited to listen to a broadcast review of the Company's fiscal 2013 second quarter and six-month financial results today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) that may be accessed by visiting the Company's website at www.pro-dex.com.  The conference call may also be accessed at www.InvestorCalendar.com. Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-8033, or at (201) 689-8033 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available approximately two hours after the completion of the call until midnight (Eastern Time) on January 24, 2013 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 407053.  An online archive of the broadcast will be available on the Company's website www.pro-dex.com for a period of 365 days.

About Pro-Dex, Inc.:Pro-Dex, Inc., with operations in California and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets.  Its OMS division designs and manufactures embedded motion control systems serving the medical, dental, semi-conductor and scientific research markets. Pro-Dex's products are found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)  PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December 31, 2012

June 30, 2012ASSETSCurrent assets:Cash

$
2,549,000

$ 4,112,000Accounts receivable, net of allowance for doubtful accounts of $13,000 at December 31, 2012 and $16,000 at June 30, 2012

1,175,000

1,581,000Other current receivables

90,000

123,000Inventories

3,515,000

2,791,000Prepaid expenses

237,000

172,000Income taxes receivable

570,000

609,000Deferred income taxes

109,000

109,000Total current assets

8,245,000

9,497,000Property, plant, equipment and leasehold improvements, net

2,290,000

2,539,000Real estate held for sale

733,000

733,000Other assets

53,000

53,000Total assets

$
,321,000

$ 12,822,000LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
576,000

$
33,000Accrued expenses

1,008,000

1,425,000Income taxes payable

47,000

47,000Bank term loan

--

774,000Total current liabilities

1,631,000

2,879,000Non-current liabilities:Deferred income taxes

109,000

109,000Deferred rent

280,000

284,000Total non-current liabilities

389,000

393,000Total liabilities

2,020,000

3,272,000Commitments and contingenciesShareholders' equity:Common shares; no par value; 50,000,000 shares authorized; 3,340,684 and 3,272,350 shares issued and outstanding at December 31, 2012 and June 30, 2012, respectively

16,962,000

16,846,000Accumulated deficit

(7,661,000)

(7,296,000)Total shareholders' equity

9,301,000

9,550,000Total liabilities and shareholders' equity

$
,321,000

$ 12,822,000 

 

 

PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS For The Three Months Ended December 31,2012

2011Net sales

$   3,007,000

$ 4,017,000Cost of sales

1,974,000

2,770,000Gross profit

1,033,000

1,247,000Operating expenses:Selling expenses

322,000

369,000General and administrative expenses

627,000

688,000Research and development costs

464,000

508,000Total operating expenses

1,413,000

1,565,000Loss from continuing operations before items below

(380,000)

(318,000)Other expense:Interest expense

--

(10,000)Total other expense

--

(10,000)Loss from continuing operations before provision for (benefit from) income taxes

(380,000)

(328,000)Provision for (benefit from) income taxes

(16,000)

1,000Loss from continuing operations

(364,000)

(329,000)Income from discontinued operations, net of provision for income taxes of $21,000 in 2012 and $0 in 2011

16,000

37,000Net loss

$
(348,000)

$ (292,000)Per share data:Loss from continuing operationsBasic

$
(0.11)

$
(0.10)Diluted

$
(0.11)

$
(0.10)Income from discontinued operationsBasic

$
--

$
.01Diluted

$
--

$
.01Net lossBasic

$
(0.11)

$
(0.09)Diluted

$
(0.11)

$
(0.09)Weighted average shares outstanding - basic

3,319,180

3,272,350Weighted average shares outstanding - diluted

3,319,180

3,272,350 

 

PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS For The Six Months Ended December 31,2012

2011Net sales

$   6,468,000

$  9,062,000Cost of sales

4,199,000

5,707,000Gross profit

2,269,000

3,355,000Operating expenses:Selling expenses

596,000

743,000General and administrative expenses

1,234,000

1,504,000Research and development costs

870,000

1,069,000Total operating expenses

2,700,000

3,316,000Income (loss) from continuing operations before items below

(431,000)

39,000Other expense:Interest expense

(6,000)

(20,000)Total other expense

(6,000)

(20,000)Income (loss) from continuing operations before provision for (benefit from) income taxes

(437,000)

19,000Provision for (benefit from) income taxes

(19,000)

2,000Income (loss) from continuing operations

(418,000)

17,000Income from discontinued operations, net of provision for income taxes of $25,000 in 2012 and $0 in 2011

53,000

137,000Net income (loss)

$
(365,000)

$
54,000Per share data:Income (loss) from continuing operationsBasic

$
(0.13)

$
.01Diluted

$
(0.13)

$
.01Income from discontinued operationsBasic

$
.02

$
.04Diluted

$
.02

$
.04Net income (loss)Basic

$
(0.11)

$
.05Diluted

$
(0.11)

$
.05Weighted average shares outstanding - basic

3,299,379

3,272,350Weighted average shares outstanding - diluted

3,299,379

3,292,508 

 

  

PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS For The Six Months Ended December 31,2012

2011Cash flows from operating activities:Net income (loss)

$
(365,000)

$
54,000Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization

298,000

339,000Allowance for doubtful accounts

(3,000)

6,000Share-based compensation

65,000

33,000Changes in:Accounts receivable and other current receivables

440,000

834,000Inventories

(724,000)

(1,030,000)Prepaid expenses

(65,000)

(88,000)Other assets

--

8,000Accounts payable and accrued expenses

(476,000)

(213,000)Income taxes receivable and payable

39,000

(49,000)Net cash used in operating activities

(791,000)

(6,000)Cash flows from investing activities:Purchases of equipment

(48,000)

(237,000)Net cash used in investing activities

(48,000)

(237,000)Cash flows from financing activities:Proceeds from exercise of stock options

50,000

--Principal payments on term loan

(774,000)

(179,000)Net cash used in financing activities

(724,000)

(179,000)Net decrease in cash

(1,563,000)

(422,000)Cash, beginning of period

4,112,000

4,689,000Cash, end of period

$
2,549,000

$
4,267,000Supplemental InformationCash payments for interest

$
9,000

$
,000Cash payments for income taxes

$
8212;

$
8212; 

 PRO-DEX, INC. and SUBSIDIARIES RECONCILIATION OF NON-GAAP DATA TO GAAP DATA Loss From Continuing Operations Before Provision For Income Taxes 

(in thousands)

(unaudited)For The Three Months Ended December 31,

For The Six Months Ended December 31,2012

2011

2012

2011Earnings before interest, taxes, depreciation and amortization ("EBITDA")

$(196,000)

$(130,000)

$(55,000)

$473,000Interest expense

--

10,000

6,000

20,000Depreciation and amortization

147,000

151,000

298,000

297,000Income from discontinued operations, before provision for income taxes of $21,000 and $25,000 for the three and six months ended December 31, 2012, respectively, and $0 for each of the three and six months ended December 31, 2011

37,000

37,000

78,000

137,000Income (loss) from continuing operations before provision for income taxes

$(380,000)

$(328,000)

$(437,000)

$19,000 

 

 


'/>"/>
SOURCE Pro-Dex, Inc.
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Pro-Dex, Inc. Announces Fiscal 2013 First Quarter Results
2. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter And Full-Year Results
3. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
4. Pro-Dex, Inc. Announces Update Conference Call and Webcast
5. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
7. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
8. Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
9. Accelr8 Announces Results of 2012 Annual Meeting
10. OncoSec Medical Announces $7.2 Million Public Offering
11. Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  As people age, ... The multitude of recommended screenings and tests that are ... a priority. However, for the majority of aging individuals, ... health planning. For the 37.5 million American adults who ... the present to make hearing health a 2016 healthy ...
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") ... POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following ... shareholders of Tribute. The combined company will operate under ... with operations in Canada , ... States . Under the terms of the Agreement ...
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... in Houma, LA, celebrates the beginning of a new charity campaign. As part ... Court Appointed Special Advocates (CASA). In the belief that children deserve a voice, ...
(Date:2/8/2016)... PISCATAWAY, N.J. (PRWEB) , ... February 08, 2016 ... ... of protective footwear and clothing, announced expansion into Canada to provide its range ... has opened a sales office in Quebec City that will provide bilingual customer ...
(Date:2/8/2016)... Atlanta, GA (PRWEB) , ... ... ... information technology and security executive networking and relationship-marketing firm, announced today that ... the 2016 Information Security Executive® (ISE®) West Awards. , Awards include ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... showing greater than 50% lower incidence rate of type 2 diabetes in the ... averages. ”It is time to make a change in public health,” states Carole ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... The AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago ... about helpful interventions and causes of chronic illness in children. , Very recent articles ...
Breaking Medicine News(10 mins):